ObsEva SA OBSV

ObsEva SA Long-Term Debt | OBSV

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt ObsEva SA

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	25.3 M	24.9 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
25.3 M	24.9 M	25.1 M

Quarterly Long-Term Debt ObsEva SA

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	240 K	-	-	-	952 K	-	-	-	1.54 M	-	1.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.84 M	240 K	1.14 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
AbbVie ABBV	64.5 B	$ 263.04	0.49 %	$ 465 B	USA
AbCellera Biologics ABCL	137 M	$ 11.41	2.15 %	$ 3.41 B	Canada
Фармсинтез LIFE	13.2 M	-	-	-	Russia
Aclaris Therapeutics ACRS	1.56 M	$ 5.53	6.02 %	$ 678 M	USA
ADC Therapeutics SA ADCT	1.03 M	$ 1.09	3.74 %	$ 139 M	Schweiz
Amryt Pharma plc AMYT	4.05 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	43.6 M	-	-14.46 %	$ 27.9 M	USA
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
Clovis Oncology CLVS	437 M	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	458 K	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	13.9 M	-	-	$ 401 M	USA
ADMA Biologics ADMA	69.3 M	$ 8.61	0.16 %	$ 2.05 B	USA
Eiger BioPharmaceuticals EIGR	39.6 M	-	-9.21 %	$ 2.55 M	USA
89bio ETNB	35.7 M	-	-	$ 1.55 B	USA
Freeline Therapeutics Holdings plc FRLN	3.26 M	-	-	$ 384 M	Britain
Fusion Pharmaceuticals FUSN	34.8 M	-	-	$ 1.41 B	Canada
Guardion Health Sciences GHSI	3.81 K	-	-0.31 %	$ 3.64 M	USA
Genocea Biosciences GNCA	4.15 M	-	-15.0 %	$ 3.04 M	USA
Gritstone Oncology GRTS	40.1 M	-	0.42 %	$ 213 M	USA
G1 Therapeutics GTHX	50 M	-	-	$ 370 M	USA
Harpoon Therapeutics HARP	13.6 M	-	-	$ 763 M	USA
Humanigen HGEN	25 M	-	-81.12 %	$ 4.28 M	USA
HOOKIPA Pharma HOOK	323 K	-	-6.92 %	$ 79.4 M	USA
Intercept Pharmaceuticals ICPT	223 M	-	-	$ 643 M	USA
IGM Biosciences IGMS	38.1 M	-	-	$ 76.9 M	USA
IMV IMV	1.12 M	-	-	$ 13.1 M	Canada
Intra-Cellular Therapies ITCI	12.7 M	-	-	$ 13.6 B	USA
Kinnate Biopharma KNTE	2.28 M	-	-	$ 123 M	USA
Chinook Therapeutics KDNY	34.5 M	-	-	$ 2.6 B	USA
Kaleido Biosciences KLDO	5.55 M	-	-3.69 %	$ 12.4 M	USA
Kronos Bio KRON	21.5 M	-	1.49 %	$ 50.8 M	USA
Karuna Therapeutics KRTX	13.8 M	-	-	$ 12.2 B	USA
La Jolla Pharmaceutical Company LJPC	164 K	-	-	$ 154 M	USA
LogicBio Therapeutics LOGC	5.01 M	-	-	$ 229 M	USA
Lumos Pharma LUMO	303 K	-	-	$ 35.3 M	USA
Merrimack Pharmaceuticals MACK	15 M	-	-	$ 216 M	USA
Stealth BioTherapeutics Corp MITO	13.7 M	-	-	$ 23.9 M	USA
Mirati Therapeutics MRTX	43.7 M	-	-	$ 3.3 B	USA
NexImmune NEXI	426 K	-	70.13 %	$ 4.12 M	USA
9 Meters Biopharma NMTR	51.4 K	-	-42.97 %	$ 1.05 M	USA
InVivo Therapeutics Holdings Corp. NVIV	553 K	-	-37.48 %	$ 476 K	USA
Nymox Pharmaceutical Corporation NYMX	931 K	-	-19.68 %	$ 18.4 M	Canada
Oncorus ONCR	20 M	-	-8.54 %	$ 3.19 M	USA
OncoSec Medical Incorporated ONCS	937 K	-	31.87 %	$ 1.61 M	USA
Oncternal Therapeutics ONCT	145 K	-	-24.12 %	$ 1.56 M	USA
Opiant Pharmaceuticals OPNT	673 K	-	-	$ 109 M	USA
Orchard Therapeutics plc ORTX	23 M	-	1.02 %	$ 90.8 M	Britain